FDA reportedly eyeing staff bonuses to accelerate drug reviews
Source: SeekingAlpha
2026-02-26 13:35:52 ET
More on leading drugmakers
- Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie
- Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade)
- Merck: Why Investors Should Remain Bullish Despite Patent Risks
- Kenvue effort to dismiss Tylenol case rejected by Texas judge
- CDC advisory meeting in March to focus on COVID-19 vaccine injuries, long COVID
Read the full article on Seeking Alpha
For further details see:
FDA reportedly eyeing staff bonuses to accelerate drug reviews
Biogen Inc.
NASDAQ: BIIB
BIIB Trading
-2.82% G/L:
$182.16 Last:
289,061 Volume:
$186.25 Open:
BIIB Latest News
March 05, 2026 07:30:00 am
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
BIIB Stock Data
$28,113,797,416
145,290,943
N/A
471
N/A
Pharmaceuticals
Healthcare
US
Cambridge
